From the Editor

Jul 01, 2011
Pharmaceutical Executive
More bad ideas on how to manage the healthcare burden are circulating beyond the stakeholders that initiated them
Jun 01, 2011
Pharmaceutical Executive
By Pharmaceutical Executive Editors
Now that government payers are turning to pharma to bridge budgetary shortfalls it's best to think long-term
May 01, 2011
Pharmaceutical Executive
By Pharmaceutical Executive Editors
What do the Pharm Exec 50 numbers tell us? The dominant theme seems to be one of gradual restructuring toward a post-patent-cliff era.
Apr 01, 2011
Pharmaceutical Executive
A true performance culture has to focus on the mundane as much as the sublime
Apr 01, 2011
Pharmaceutical Executive
Dutch-based DSM N.V. is seeking innovatinve ways to partner through bolstering manufacturing
Mar 01, 2011
Pharmaceutical Executive
Pharma can be an insular industry, with limited capacity to gaze beyond its own narrow frame of vision
Feb 04, 2011
Pharmaceutical Executive
"Tops in Fraud" is a ruinous moniker for pharma—a business so dependent on basic issues of trust, integrity, quality and safety
Jan 01, 2011
Pharmaceutical Executive
"Tops in Fraud" is a ruinous moniker for pharma—a business so dependent on basic issues of trust, integrity, quality and safety
Dec 01, 2010
Pharmaceutical Executive
The end of anther year is an appropriate time to highlight the march of time, and the transitions that accompany it
Nov 01, 2010
Pharmaceutical Executive
By Pharmaceutical Executive Editors
The FDA process itself is looking more like the unsavory 'sausage factory' associated with drafting partisan legislation
native1_300x100
lorem ipsum